SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
|
SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Change in Forecast SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin SCHOTT Pharma specifies FY 2025 guidance:
For further information and preliminary Q3/9M 2025 financial results we refer to our supplemental press release. The full set of Q3/9M 2025 financial results will be published on August 12, 2025. Contact Lea Kaiser PR & Communications Manager Tel.: +49 (0) 151 68917195 E-Mail: lea.kaiser@schott.com Tobias Erfurth Head of Investor Relations E-Mail: ir.pharma@schott.com Jasko Terzic, CFA Senior Manager Investor Relations E-Mail: ir.pharma@schott.com End of Inside Information
05-Aug-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2179338 |
| End of Announcement | EQS News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: